Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

Lonza Biologics plc, one of The Lonza Group's four biologic contracting manufacturing sites, is a leading contract manufacturer of monoclonal antibodies, recombinant proteins, and diagnostic monoclonal antibodies that are used to produce pharmaceuticals. Lonza Biologics conducts research and development on mammalian cell culturing involving cloning from non-animal origins. From its manufacturing facility near London, the company also supplies its products to other biotechnology companies.

Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina. Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials.

4Life Research wants to protect the health of bipeds and quadrupeds alike. The multilevel marketing company manufactures nutritional supplements for humans and animals and sells them through its global network of independent distributors. The company's flagship product is Transfer Factor, a supplement made from egg yolks and cow colostrum that is meant to enhance the body's immune system. The firm makes Transfer Factor formulations for humans, dogs, cats, horses, and livestock. The privately-held company was founded in 1998 by CEO David Lisonbee, who had previous experience with multi-level marketing organizations.

Immunomedics, Inc. company was founded in 1982 and is headquartered in Morris Plains, New Jersey. Immunomedics, Inc. (Immunomedics) is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has developed a number of advanced technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents. Immunomedics has licensed its product candidate epratuzumab, to UCB S.A. (UCB), for the treatment of all autoimmune disease indications worldwide. Epratuzumab’s most advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE), and in non-Hodgkin’s lymphoma (NHL). The Company has antibody product candidates in clinical development targeting B-cell NHL, other B-cell mediated diseases and various solid tumors.

Acusphere, Inc. is a specialty pharmaceutical company that develops drugs and formulations of existing drugs using its porous microparticle technology. This technology enables the Company to control the size and porosity of particles, including nanoparticles and microparticles, so that the particles can be customized to address the delivery needs of a variety of drugs. These product candidates include Imagify (perflubutane polymer microspheres for delivery in an injectable suspension, formerly known as AI-700), a cardiovascular drug for the detection of coronary artery disease; Hydrophobic Drug Delivery System (HDDS), which converts drugs that do not dissolve well in water into microparticles or nanoparticles of the drugs embedded in small microparticles; and Pulmonary Drug Delivery System (PDDS).

Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuit to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine.

The US subsidiary of pharmaceuticals and materials giant Bayer AG (or Bayer Group), Bayer Corporation operates through three divisions and an internal services company. Bayer Corporation handles Bayer Group's US operations in three segments: Bayer HealthCare (pharmaceuticals, animal health, and over-the-counter medicines), MaterialScience (plastics, coatings, and polyurethanes), and Bayer CropScience (herbicides, fungicides, and insecticides). The internal services unit, Bayer Corporate and Business Services, handles administrative, technology, human resources, legal, and procurement functions for the Bayer Group's US operations.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.

Natural Alternatives International, Inc. company was founded in 1980 and is headquartered in San Marcos, California. Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. It offers strategic partnering services, including customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats, and labeling design. The company also develops, manufactures, and markets its own branded products under the Pathway to Healing product line through print media and the Internet distribution channels. It manufactures products in various forms, including capsules, tablets, chewable wafers, and powders.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.